• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169542 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  5 z& {2 ?: a9 v$ h9 z% u

3 m' }# t9 K, H: m3 \" Z- }2 w* [# E* z+ b3 E0 g, Q6 d/ u
Sub-category:
  ]; E  M! I8 T. o8 nMolecular Targets
$ L2 u# B/ e+ @
# C5 e" C' A) b
/ U  G* z# P7 hCategory:
. o! |# u! }' v) B# LTumor Biology
/ h6 }; C9 D9 o
- {0 \' E. q0 [. {' e& K# l  t" ]! N5 A0 Q9 s
Meeting:1 g6 a5 l+ V9 k7 `( Q2 I
2011 ASCO Annual Meeting
: }$ F" \) `$ e+ x4 G8 g: j# z% p4 x& [7 Q7 y8 r! O, F

7 M9 }% J3 Y$ B6 U7 J( T2 \Session Type and Session Title:- D' ^5 w' M3 ^6 E* D2 U( K6 B+ I+ o2 M
Poster Discussion Session, Tumor Biology
* N$ P* B& R1 |  Y4 j2 M
( `; B7 P" c! Q/ ]
9 h0 v, M. U9 f3 NAbstract No:
, W7 X7 P$ `2 P$ i10517
, \! P: V" ^0 x& I/ l( s7 C/ g" ]7 G1 s3 t& v) E" ?* r

( w  o% z! W$ T- M7 j% h; d: F4 JCitation:
' ^0 ?$ F$ K- \6 J* HJ Clin Oncol 29: 2011 (suppl; abstr 10517) 7 h* }! p8 o+ V$ y9 H3 T" _

8 @- \# p* d* H: {2 B* F2 D
& W+ x: K6 G/ r8 |2 z; AAuthor(s):
6 l- j+ j" B7 C' J4 j/ ~J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China   N5 U3 y: j5 B

7 g% Q6 P% k( {
; j, W8 t: I) ^$ h3 k/ D& ^# ?; ]" P6 ]9 I
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.* S  |, |9 Y5 `4 Y( q" A5 ^- C0 z

) |7 c9 O- ~" ]7 J# A* ^Abstract Disclosures
( Q5 ?9 |; i0 Q
/ K/ ]2 N9 f# J  ]Abstract:% e# A7 }+ B2 ]+ d1 m* q' i! o/ B

8 ?7 S; O, p  _
  Z6 Q4 L; k( |8 s8 @/ O3 fBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 u5 ?4 ~) ?; j8 l1 n; U% r
2 i8 Z. v7 X; E/ \9 B" T' T

& {0 d( U1 m% A  }' J4 l) B9 N
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 s; e6 E# m* z6 j$ e3 p' _( y没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
6 b% M. h) ~- P; S
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
5 K, E% ]) n' G5 j易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
% K4 j, O0 {) |; BALK一个指标医院要900多 ...
; k3 Q% U7 }" a7 f* U2 Q3 H* @, ?
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?  T- w- ?8 t4 F; l' l6 U

5 ^' d# L( {2 m2 c/ ]现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表